Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

TORONTO –(BUSINESS WIRE)–Dec. 18, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily

Cybin to Participate in the Jefferies Global Healthcare Conference in London

TORONTO –(BUSINESS WIRE)–Nov. 12, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

– Chief Medical Officer Amir Inamdar to participate in a panel on November 5, 2025 – TORONTO –(BUSINESS WIRE)–Nov. 3, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental

Cybin Announces Closing of $175 Million Registered Direct Offering

TORONTO –(BUSINESS WIRE)–Oct. 31, 2025– Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) (“ Cybin ” or the “ Company ”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative

Cybin Announces $175 Million Registered Direct Offering

– Funding of Clinical Stage Programs with Participation from Prominent Biotech Investors – – Use of Proceeds Includes Repayment of High Trail Convertible Note in Full – TORONTO –(BUSINESS WIRE)–Oct. 28, 2025– Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) (“ Cybin ” or the “ Company ”), a

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

– Successfully completed enrollment of 36 participants in Phase 2 study of CYB004, the Company’s deuterated dimethyltryptamine (“DMT”) program for the treatment of Generalized Anxiety Disorder (“GAD”). Topline data expected Q1 2026 – – Continues to advance CYB003, the Company’s proprietary